Propensity-Matched Study of Early Cardiac Rehabilitation in Patients With Acute Decompensated Heart Failure.

"Disclosures Dr Ide is an endowed chair funded by Actelion Pharmaceuticals. Dr Tsutsui reports personal fees from MSD, Astellas, Pfizer, Bristol Myers Squibb, Otsuka Pharmaceutical, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Takeda Pharmaceutical, Bayer Yakuhin, Novartis Pharma, Kowa Pharmaceutical, Teijin Pharma, Medical Review Co, and Japanese Journal of Clinical Medicine; nonfinancial support from Actelion Pharmaceuticals, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Daiichi-Sankyo, IQVIA Services Japan, and Omron Healthcare Co; and grants from Astellas, Novartis Pharma, Daiichi-Sankyo, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Teijin Pharma, and MSD, outside the submitted work. The other authors declare no conflicts of interest associated with this article."

"Sources of Funding This work was supported by the Japan Agency for Medical Research and Development Grant (19ek0210080h0003 [Dr Tsutsui]) and Health Sciences Research Grants from the Japanese Ministry of Health, Labour, and Welfare (Comprehensive Research on Cardiovascular Diseases; 20FC1051 [Dr Tsutsui]). The funders had no role in the design and conduct of the study or in collection, management, analysis, and interpretation of the data, the preparation, review, and submission of the article for publication."